Metformin and the Biology of Aging with Nir Barzilai, MD

Apr 11, 2021

Ask episode

Chapters

Transcript

Episode notes

In this episode, Daniel Belkin and Mitch Belkin interview Nir Barzilai, MD, the founding director of the Institute for Aging Research and an expert in the genetics of longevity. Dr. Barzilai is a professor in the departments of Medicine and Genetics at the Albert Einstein College of Medicine. He is the recipient of numerous awards and grants. He has published over 230 peer-reviewed papers, reviews, and textbook chapters, as well as the book Age Later.

In this interview, we discuss the field of gero-therapeutics, the hallmarks of aging, and gender differences in aging. We review his work on centenarians and what they can teach us about the genetics of longevity. Finally, we delve into metformin, its use as an anti-aging therapy, its mechanism of action and the TAME trial, on which he is the primary investigator.

To learn more about the latest in aging-related research, check out the American Federation of Aging. This interview was recorded on March 26, 2021.

Centenarian studies:

The Longevity Genes Project is geared at understanding which genetic factors contribute to exceptionally long life. The project focuses on Ashkenazi “super agers”–people between the ages of 95 and 112–to determine how their genetics differ from controls without exceptional longevity. In addition, the study follows the children of “super agers” with matched controls.

What is Metformin?

Metformin (Glucophage) is a biguanide that is a first-line treatment for type 2 diabetes. While it has many mechanisms of action, its primary mechanisms of action are believed to be (1) decreasing hepatic glucose production by inhibiting gluconeogenesis, (2) inhibiting complex I of the electron transport chain, and (3) inhibiting the mammalian target of rapamycin (mTOR) signaling pathway. It is the 4th most prescribed medication in the United States. Metformin use is associated with a reduction in the incidence of cancer. It is also associated with reductions in cognitive decline and Alzheimer’s among diabetics.

If you are interested in learning more about how metformin attenuates the hallmarks of aging, Nir Barzilai wrote a paper in cell metabolism: Benefits of Metformin in Attenuating the Hallmarks of Aging (2020).

What is the TAME Trial?

The Targeting Aging with Metformin (TAME) Trial is a placebo-controlled clinical trial designed to determine whether taking metformin delays the development or progression of age-related chronic diseases, including heart disease, cancer, and dementia. The study population will include 3,000 individuals at 14 sites across the U.S. who are between the ages of 65-79. Patients will receive either 1500mg Metformin daily or a placebo for up to 6 years.

What is the External Medicine Podcast?

The External Medicine Podcast explores some of the most exciting ideas in medicine. Co-hosted by Daniel Belkin, MD,

Support the show